Peptide Database

Category: FAT LOSS / LEAN MUSCLE

Description

BEST BLEND FOR OVERALL BODY AND ANTI-AGING MIXED WITH HEAVY WEIGHT LOSS NEEDS

Specifications

Amount in Vial: 15MG

BAC Water: 1ML

Amount per Unit: 0.15MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 1.5MG TO 4.5MG (10 TO 30 UNITS)

Frequency: 5 DAYS ON 2 OFF

Timing: Fasted - 45 Minutes Before and After Injection

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.15MG PER UNIT

Category: FAT LOSS / LEAN MUSCLE

Description

GREAT BLEND FOR ATHLETE TRYING TO PUT ON LEAN MUSCLE TISSUE AND FAT TO MUSCLE CONVERSION

Specifications

Amount in Vial: 10MG

BAC Water: 1ML

Amount per Unit: 0.1MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 2MG TO 4MG (20 TO 40 UNITS)

Frequency: 5 DAYS ON 2 OFF

Timing: Fasted - 45 Minutes Before and After Injection

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.1MG PER UNIT

Category: FAT LOSS / LEAN MUSCLE

Description

GREAT BLEND FOR MUSCLE RETENTION, ANTI AGING AND LOSING FAT IN STUBBORN SPOTS

Specifications

Amount in Vial: 10MG

BAC Water: 1ML

Amount per Unit: 0.1MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 2MG TO 4MG (20 TO 40 UNITS)

Frequency: 5 DAYS ON 2 OFF

Timing: Fasted - 45 Minutes Before and After Injection

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.1MG PER UNIT

Category: FAT LOSS / LEAN MUSCLE

Description

BEST BLEND FOR THE ATHLETE LOOKING TO COMPETE, RECOVERY AND ANTI AGING WHILE ADDING LEAN MUSCLE MASS

Specifications

Amount in Vial: 8MG

BAC Water: 1ML

Amount per Unit: 0.08MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 1.6MG TO 3.2MG (20 TO 40 UNITS)

Frequency: 5 DAYS ON 2 OFF

Timing: Fasted - 45 Minutes Before and After Injection

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.08MG PER UNIT

Category: FAT LOSS / LEAN MUSCLE

Description

BULKING BLEND TO INCREASE MUSCLE MASS WHILE INCREASING APPETITE

Specifications

Amount in Vial: 13MG

BAC Water: 1ML

Amount per Unit: 0.13MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 2.6MG TO 5.2MG (20 TO 40 UNITS)

Frequency: 5 DAYS ON 2 OFF

Timing: Fasted - 45 Minutes Before and After Injection

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.13MG PER UNIT

Category: WEIGHT MANAGEMENT

Description

GLP-1 (glucagon-like peptide-1) is an incretin hormone naturally released by the gut after eating. As a receptor agonist, it enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and signals the brain's hypothalamus to reduce appetite — all through binding to GLP-1 receptors expressed in the pancreas, brain, gut, and adipose tissue. Brain-mediated appetite suppression is now considered the primary driver of its weight loss effects, with preclinical research showing that GLP-1 action restricted to the brain alone still produces significant food intake reduction. Phase 3 clinical trials with GLP-1 agonists have demonstrated mean body weight reductions of approximately 15% over 68 weeks, with approximately 50% of participants achieving 15% or more weight loss. Common research side effects include nausea, vomiting, and constipation, particularly during dose titration — which is why starting doses are low and titrated upward gradually. For research and educational purposes only. Consult a qualified healthcare professional.

Specifications

Amount in Vial: 2MG

BAC Water: 1ML

Amount per Unit: 0.02MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: TITRATE UP FROM 250MCG TO 2.5MG (12 TO 125 UNITS)

Frequency: 1X PER WEEK

Timing: Same Day Every Week / Starting Dose Is 250 MCG

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.02MG PER UNIT

Category: WEIGHT MANAGEMENT

Description

GLP-1 (glucagon-like peptide-1) is an incretin hormone naturally released by the gut after eating. As a receptor agonist, it enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and signals the brain's hypothalamus to reduce appetite — all through binding to GLP-1 receptors expressed in the pancreas, brain, gut, and adipose tissue. Brain-mediated appetite suppression is now considered the primary driver of its weight loss effects, with preclinical research showing that GLP-1 action restricted to the brain alone still produces significant food intake reduction. Phase 3 clinical trials with GLP-1 agonists have demonstrated mean body weight reductions of approximately 15% over 68 weeks, with approximately 50% of participants achieving 15% or more weight loss. Common research side effects include nausea, vomiting, and constipation, particularly during dose titration — which is why starting doses are low and titrated upward gradually. For research and educational purposes only. Consult a qualified healthcare professional.

Specifications

Amount in Vial: 5MG

BAC Water: 1ML

Amount per Unit: 0.05MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: TITRATE UP FROM 250MCG TO 2.5MG (5 TO 50 UNITS)

Frequency: 1X PER WEEK

Timing: Same Day Every Week / Starting Dose Is 250 MCG

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.05MG PER UNIT

Category: WEIGHT MANAGEMENT

Description

GLP-1 (glucagon-like peptide-1) is an incretin hormone naturally released by the gut after eating. As a receptor agonist, it enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and signals the brain's hypothalamus to reduce appetite — all through binding to GLP-1 receptors expressed in the pancreas, brain, gut, and adipose tissue. Brain-mediated appetite suppression is now considered the primary driver of its weight loss effects, with preclinical research showing that GLP-1 action restricted to the brain alone still produces significant food intake reduction. Phase 3 clinical trials with GLP-1 agonists have demonstrated mean body weight reductions of approximately 15% over 68 weeks, with approximately 50% of participants achieving 15% or more weight loss. Common research side effects include nausea, vomiting, and constipation, particularly during dose titration — which is why starting doses are low and titrated upward gradually. For research and educational purposes only. Consult a qualified healthcare professional.

Specifications

Amount in Vial: 10MG

BAC Water: 2ML

Amount per Unit: 0.05MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: TITRATE UP FROM 250MCG TO 2.5MG (5 TO 50 UNITS)

Frequency: 1X PER WEEK

Timing: Same Day Every Week / Starting Dose Is 250 MCG

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.05MG PER UNIT

Category: WEIGHT MANAGEMENT

Description

GLP-1 (glucagon-like peptide-1) is an incretin hormone naturally released by the gut after eating. As a receptor agonist, it enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and signals the brain's hypothalamus to reduce appetite — all through binding to GLP-1 receptors expressed in the pancreas, brain, gut, and adipose tissue. Brain-mediated appetite suppression is now considered the primary driver of its weight loss effects, with preclinical research showing that GLP-1 action restricted to the brain alone still produces significant food intake reduction. Phase 3 clinical trials with GLP-1 agonists have demonstrated mean body weight reductions of approximately 15% over 68 weeks, with approximately 50% of participants achieving 15% or more weight loss. Common research side effects include nausea, vomiting, and constipation, particularly during dose titration — which is why starting doses are low and titrated upward gradually. For research and educational purposes only. Consult a qualified healthcare professional.

Specifications

Amount in Vial: 20MG

BAC Water: 4ML

Amount per Unit: 0.05MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: TITRATE UP FROM 250MCG TO 2.5MG (5 TO 50 UNITS)

Frequency: 1X PER WEEK

Timing: Same Day Every Week / Starting Dose Is 250 MCG

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.05MG PER UNIT

Category: WEIGHT MANAGEMENT

Description

GLP-1 Dual Agonist peptides target both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously. GLP-1 and GIP receptors are co-expressed in the brain, pancreatic beta cells, adipose tissue, and other metabolic tissues. Activating both pathways produces synergistic — not merely additive — metabolic effects, because each receptor pathway converges on overlapping cellular machinery. The dual mechanism results in greater appetite suppression, enhanced insulin secretion, better glycemic control, and more pronounced fat oxidation compared to single GLP-1 agonism alone. Phase 3 clinical trials with dual GIP/GLP-1 agonists showed average body weight reductions of 20–21% at maximum doses, with 91% of participants achieving at least 5% weight loss. Gastrointestinal side effects are typically milder than with GLP-1 mono-agonists due to the complementary GIP receptor mechanism. For research and educational purposes only. Not FDA-approved for all formulations. Consult a qualified healthcare professional.

Specifications

Amount in Vial: 10MG

BAC Water: 1ML

Amount per Unit: 0.1MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: TITRATE UP FROM 2.5MG TO 10MG (25 TO 100 UNITS)

Frequency: 1X PER WEEK

Timing: Same Day Every Week / Starting Dose Is 2.5 MG

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.1MG PER UNIT

Category: WEIGHT MANAGEMENT

Description

GLP-1 Dual Agonist peptides target both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously. GLP-1 and GIP receptors are co-expressed in the brain, pancreatic beta cells, adipose tissue, and other metabolic tissues. Activating both pathways produces synergistic — not merely additive — metabolic effects, because each receptor pathway converges on overlapping cellular machinery. The dual mechanism results in greater appetite suppression, enhanced insulin secretion, better glycemic control, and more pronounced fat oxidation compared to single GLP-1 agonism alone. Phase 3 clinical trials with dual GIP/GLP-1 agonists showed average body weight reductions of 20–21% at maximum doses, with 91% of participants achieving at least 5% weight loss. Gastrointestinal side effects are typically milder than with GLP-1 mono-agonists due to the complementary GIP receptor mechanism. For research and educational purposes only. Not FDA-approved for all formulations. Consult a qualified healthcare professional.

Specifications

Amount in Vial: 30MG

BAC Water: 3ML

Amount per Unit: 0.1MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: TITRATE UP FROM 2.5MG TO 15MG (25 TO 150 UNITS)

Frequency: 1X PER WEEK

Timing: Same Day Every Week / Starting Dose Is 2.5 MG

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.1MG PER UNIT

Category: WEIGHT MANAGEMENT

Description

GLP-1 Dual Agonist peptides target both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously. GLP-1 and GIP receptors are co-expressed in the brain, pancreatic beta cells, adipose tissue, and other metabolic tissues. Activating both pathways produces synergistic — not merely additive — metabolic effects, because each receptor pathway converges on overlapping cellular machinery. The dual mechanism results in greater appetite suppression, enhanced insulin secretion, better glycemic control, and more pronounced fat oxidation compared to single GLP-1 agonism alone. Phase 3 clinical trials with dual GIP/GLP-1 agonists showed average body weight reductions of 20–21% at maximum doses, with 91% of participants achieving at least 5% weight loss. Gastrointestinal side effects are typically milder than with GLP-1 mono-agonists due to the complementary GIP receptor mechanism. For research and educational purposes only. Not FDA-approved for all formulations. Consult a qualified healthcare professional.

Specifications

Amount in Vial: 50MG

BAC Water: 3ML

Amount per Unit: 0.17MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: TITRATE UP FROM 2.5MG TO 15MG (15 TO 90 UNITS)

Frequency: 1X PER WEEK

Timing: Same Day Every Week / Starting Dose Is 2.5 MG

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.17MG PER UNIT

Category: WEIGHT MANAGEMENT

Description

GLP-1 Dual Agonist peptides target both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously. GLP-1 and GIP receptors are co-expressed in the brain, pancreatic beta cells, adipose tissue, and other metabolic tissues. Activating both pathways produces synergistic — not merely additive — metabolic effects, because each receptor pathway converges on overlapping cellular machinery. The dual mechanism results in greater appetite suppression, enhanced insulin secretion, better glycemic control, and more pronounced fat oxidation compared to single GLP-1 agonism alone. Phase 3 clinical trials with dual GIP/GLP-1 agonists showed average body weight reductions of 20–21% at maximum doses, with 91% of participants achieving at least 5% weight loss. Gastrointestinal side effects are typically milder than with GLP-1 mono-agonists due to the complementary GIP receptor mechanism. For research and educational purposes only. Not FDA-approved for all formulations. Consult a qualified healthcare professional.

Specifications

Amount in Vial: 60MG

BAC Water: 3ML

Amount per Unit: 0.2MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: TITRATE UP FROM 2.5MG TO 15MG (12.5 TO 75 UNITS)

Frequency: 1X PER WEEK

Timing: Same Day Every Week / Starting Dose Is 2.5 MG

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.2MG PER UNIT

Category: WEIGHT MANAGEMENT

Description

GLP-3 class peptides are triple receptor agonists targeting GLP-1, GIP, and glucagon receptors simultaneously. Adding glucagon receptor activation to the dual GLP-1/GIP mechanism introduces a third lever: glucagon signaling increases energy expenditure and hepatic fat metabolism, which further amplifies the fat-reduction signal beyond what dual agonists achieve. The three receptor pathways work synergistically across the brain, liver, pancreas, and adipose tissue. Phase 2 clinical research on triple agonists showed mean body weight reduction of 24.2% at 48 weeks, with participants still losing weight at study end — indicating a plateau had not yet been reached. Phase 3 data has since reported up to 28.7% weight loss. The glucagon component also increases energy expenditure, which researchers propose may explain the energy and cognitive benefits often reported alongside weight reduction. Gastrointestinal tolerability is generally comparable to dual agonists. For research and educational purposes only.

Specifications

Amount in Vial: 12MG

BAC Water: 1.2ML

Amount per Unit: 0.1MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: TITRATE UP FROM 2MG TO 12MG (20 TO 120 UNITS)

Frequency: 1X PER WEEK

Timing: Same Day Every Week / Starting Dose Is 2 MG

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.1MG PER UNIT

Category: WEIGHT MANAGEMENT

Description

GLP-3 class peptides are triple receptor agonists targeting GLP-1, GIP, and glucagon receptors simultaneously. Adding glucagon receptor activation to the dual GLP-1/GIP mechanism introduces a third lever: glucagon signaling increases energy expenditure and hepatic fat metabolism, which further amplifies the fat-reduction signal beyond what dual agonists achieve. The three receptor pathways work synergistically across the brain, liver, pancreas, and adipose tissue. Phase 2 clinical research on triple agonists showed mean body weight reduction of 24.2% at 48 weeks, with participants still losing weight at study end — indicating a plateau had not yet been reached. Phase 3 data has since reported up to 28.7% weight loss. The glucagon component also increases energy expenditure, which researchers propose may explain the energy and cognitive benefits often reported alongside weight reduction. Gastrointestinal tolerability is generally comparable to dual agonists. For research and educational purposes only.

Specifications

Amount in Vial: 24MG

BAC Water: 2.4ML

Amount per Unit: 0.1MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: TITRATE UP FROM 2MG TO 12MG (20 TO 120 UNITS)

Frequency: 1X PER WEEK

Timing: Same Day Every Week / Starting Dose Is 2 MG

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.1MG PER UNIT

Category: WEIGHT MANAGEMENT

Description

Survodutide is a dual agonist of the GLP-1 and glucagon receptors — a distinct mechanism from the GLP-1/GIP dual agonist class. Where GIP receptor activation enhances insulin sensitivity and fat storage regulation, glucagon receptor activation increases hepatic glucose output and energy expenditure. This pairing makes survodutide particularly relevant in research focused on metabolic liver disease, including non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatohepatitis (MASH), in addition to weight loss. Its Phase 3 trial results are pending as of 2025. The glucagon component is associated with increased resting energy expenditure, which may explain the chronic fatigue benefits observed in preliminary research. For research and educational purposes only.

Specifications

Amount in Vial: 6MG

BAC Water: 1ML

Amount per Unit: 0.06MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: TITRATE UP FROM 600MCG TO 4.5MG (10 TO 75 UNITS)

Frequency: 1X PER WEEK

Timing: Same Day Every Week / Starting Dose Is 600MCG

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.06MG PER UNIT

Category: WEIGHT MANAGEMENT

Description

STIMULATES LYPOSIS (BREAKDOWN OF FAT) DOES NOT ENHANCE HUNGER OR BLOOD SUGAR LEVELS GREAT TO STACK WITH OTHER PEPTIDES

Specifications

Amount in Vial: 5MG

BAC Water: 2ML

Amount per Unit: 0.025MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 500MCG TO 1MG (20 TO 40 UNITS)

Frequency: 5 DAYS ON 2 OFF

Timing: Fasted Before Bed or Upon Waking (Fasted Cardio)

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.025MG PER UNIT

Category: WEIGHT MANAGEMENT

Description

Cagrilintide is a long-acting amylin analogue — amylin is a peptide hormone co-secreted with insulin by pancreatic beta cells. It binds amylin receptors in the hypothalamus and brainstem to reduce food intake, slow gastric emptying, and suppress glucagon. Its pharmacological half-life allows once-weekly dosing. Cagrilintide is most extensively studied in combination with semaglutide (the combination is called CagriSema, developed by Novo Nordisk). Phase 3 REDEFINE-1 trial results showed CagriSema produced approximately 20.4% weight loss — greater than either agent alone — with a new drug application submitted to the FDA in December 2025. When added to existing GLP-1 protocols, cagrilintide may allow GLP-1 dose reduction while maintaining or enhancing weight loss outcomes, potentially reducing dose-dependent nausea. Research also suggests amylin receptor activation may independently improve insulin sensitivity beyond its appetite effects. For research and educational purposes only.

Specifications

Amount in Vial: 10MG

BAC Water: 2ML

Amount per Unit: 0.05MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 300MCG TO 4.5MG (6 TO 90 UNITS)

Frequency: ONCE PER WEEK

Timing: Can Be Added To GLP To Reduce That Dosage

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.05MG PER UNIT

Category: GROWTH HORMONE RELEASING HORMONE

Description

INCREASES ENDOGENOUS IGF-1 - MINIMAL EFFECTS ON GHRELIN - THERMOGENIC - INCREASE MUSCLE MASS

Specifications

Amount in Vial: 10MG

BAC Water: 2ML

Amount per Unit: 0.05MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 1MG TO 2MG (10 TO 20 UNITS)

Frequency: 5 DAYS ON 2 OFF

Timing: Fasted Before Bed or Upon Waking

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.05MG PER UNIT

Category: GROWTH HORMONE RELEASING HORMONE

Description

INCREASES ENDOGENOUS IGF-1 - MINIMAL EFFECTS ON GHRELIN - THERMOGENIC - INCREASE MUSCLE MASS

Specifications

Amount in Vial: 10MG

BAC Water: 1ML

Amount per Unit: 0.1MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 2MG TO 4MG (20 TO 40 UNITS)

Frequency: 1 TO 2 TIMES PER WEEK

Timing: No More Than 4MG Per Week

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.1MG PER UNIT

Category: GROWTH HORMONE RELEASING HORMONE

Description

STIMULATES THE RELEASE OF ENDOGENOUS GROWTH HORMONE - INCREASED IGF-1 - DECREASE VISCERAL FAT

Specifications

Amount in Vial: 5MG

BAC Water: 1ML

Amount per Unit: 0.1MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 1MG TO 2MG (10 TO 20 UNITS)

Frequency: 5 DAYS ON 2 OFF

Timing: Taken Before Bedtime

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.1MG PER UNIT

Category: GROWTH HORMONE RELEASING HORMONE

Description

STIMULATES THE RELEASE OF ENDOGENOUS GROWTH HORMONE - INCREASED IGF-1 - DECREASE VISCERAL FAT

Specifications

Amount in Vial: 10MG

BAC Water: 1ML

Amount per Unit: 0.1MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 1MG TO 2MG (10 TO 20 UNITS)

Frequency: 5 DAYS ON 2 OFF

Timing: Taken Before Bedtime

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.1MG PER UNIT

Category: GROWTH HORMONE RELEASING HORMONE

Description

STIMULATES THE RELEASE OF ENDOGENOUS GROWTH HORMONE - IMPROVED MUSCLE STRENGTH, GROWTH AND REPAIR - ANTI AGING - IMPROVED BONE DENSITY

Specifications

Amount in Vial: 10MG

BAC Water: 2ML

Amount per Unit: 0.05MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 500MCG TO 2MG (10 TO 40 UNITS)

Frequency: 5 DAYS ON 2 OFF

Timing: Fasted - 2 Hours Before First Meal or Before Bed or Split

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.05MG PER UNIT

Category: GROWTH HORMONE RELEASING HORMONE

Description

STIMULATES THE RELEASE OF ENDOGENOUS GROWTH HORMONE - IMPROVED MUSCLE STRENGTH, GROWTH AND REPAIR - ANTI AGING - IMPROVED BONE DENSITY

Specifications

Amount in Vial: 5MG

BAC Water: 1ML

Amount per Unit: 0.05MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 500MCG TO 2MG (10 TO 40 UNITS)

Frequency: 5 DAYS ON 2 OFF

Timing: Fasted - 2 Hours Before First Meal or Before Bed or Split

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.05MG PER UNIT

Category: GROWTH HORMONE RELEASING PEPTIDE

Description

SECOND STRONGEST GHRP - STIMULATES THE RELEASE OF ENDOGENOUS GROWTH HORMONE AND GHRELIN - PROMOTES MUSCLE GROWTH

Specifications

Amount in Vial: 5MG

BAC Water: 2ML

Amount per Unit: 0.025MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 150MCG TO 300MCG (6 TO 12 UNITS)

Frequency: AS NEEDED

Timing: Multiple Times a Day as Needed Before Meals

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.025MG PER UNIT

Category: GROWTH HORMONE RELEASING PEPTIDE

Description

THIRD STRONGEST GHRP - STIMULATES THE RELEASE OF ENDOGENOUS GROWTH HORMONE AND GHRELIN - PROMOTES MUSCLE GROWTH - INCREASED APPETITE

Specifications

Amount in Vial: 5MG

BAC Water: 2ML

Amount per Unit: 0.025MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 150MCG TO 300MCG (6 TO 12 UNITS)

Frequency: AS NEEDED

Timing: Multiple Times a Day as Needed Before Meals

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.025MG PER UNIT

Category: GROWTH HORMONE RELEASING PEPTIDE

Description

STIMULATES THE RELEASE OF ENDOGENOUS GROWTH HORMONE, WITHOUT INCREASE OF APPETITE, CORTISOL OR PROLACTIN - PROMOTES MUSCLE GROWTH

Specifications

Amount in Vial: 10MG

BAC Water: 2ML

Amount per Unit: 0.05MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 200MCG TO 300MCG (4 TO 6 UNITS)

Frequency: 5 DAYS ON 2 OFF

Timing: Fasted - 30 Minutes Before Each Meal Up To 3 Times A Day

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.05MG PER UNIT

Category: GROWTH HORMONE RELEASING PEPTIDE

Description

MOST POTENT GHRP - STIMULATES RELEASE OF GROWTH HORMONE WITHOUT INCREASE OF APPETITE - PROMOTES MUSCLE GROWTH

Specifications

Amount in Vial: 5MG

BAC Water: 2ML

Amount per Unit: 0.025MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 100MCG (3X DAY) (4 UNITS)

Frequency: 3 TIMES A DAY FOR 20 WEEKS

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.025MG PER UNIT

Category: HUMAN GROWTH HORMONE

Description

EXOGENOUS HUMAN GROWTH HORMONE - MUSCLE GROWTH - BONE DENSITY - REGULATES METABOLISM BY PROMOTING LYPOSIS

Specifications

Amount in Vial: 10IU

BAC Water: 1ML

Amount per Unit: 0.1IU PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 2IU TO 6IU (20 TO 60 UNITS)

Frequency: 5 DAYS ON 2 OFF or 3 DAYS ON 1 DAY OFF

Timing: Fasted - 45 Minutes Before and After Injection

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.1IU PER UNIT

Category: INSULIN LIKE GROWTH FACTOR

Description

WORKS BY BINDING TO IGF-1 RECEPTORS - BUILDS MUSCLE - BURNS FAT - INCREASED METABOLISM - MUSCLE RECOVERY AND REPAIR

Specifications

Amount in Vial: 1MG

BAC Water: 1ML

Amount per Unit: 0.01MG PER UNIT

Injection Type: INTRAMUSCULAR

Recommended Dose: 100MCG TO 200MCG (10 TO 20 UNITS)

Frequency: 5 DAY ON 2 OFF

Timing: After Meal / Before Gym

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.01MG PER UNIT

Category: INSULIN LIKE GROWTH FACTOR

Description

IGF1-DES (des(1-3)IGF-1) is a naturally occurring truncated variant of insulin-like growth factor 1, lacking the first three N-terminal amino acids. This structural difference makes it approximately 10 times more potent than standard IGF-1 at binding IGF-1 receptors, because the truncation reduces binding to IGF binding proteins (IGFBPs) that normally regulate IGF-1 availability. As a result, a greater proportion of IGF1-DES reaches free receptor sites. It shares IGF-1's core mechanisms: stimulating protein synthesis, promoting satellite cell activation and muscle fiber hypertrophy, increasing glucose uptake in muscle tissue, and supporting fat metabolism. Its faster receptor binding and reduced IGFBP interference make it particularly relevant in research focused on local muscle tissue effects when administered intramuscularly near target sites. For research and educational purposes only.

Specifications

Amount in Vial: 1MG

BAC Water: 1ML

Amount per Unit: 0.01MG PER UNIT

Injection Type: INTRAMUSCULAR

Recommended Dose: 100MCG TO 200MCG (10 TO 20 UNITS)

Frequency: 5 DAY ON 2 OFF

Timing: After Meal / Before Gym

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.01MG PER UNIT

Category: GONADOTROPIN RELEASING HORMONE

Description

STIMULATES GONADOTROPIN RELEASE - RELEASES LH AND FSH PROMOTING THE PRODUCTION OF TESTOSTERONE - TREATS HYPOGONADISM

Specifications

Amount in Vial: 5MG

BAC Water: 2ML

Amount per Unit: 0.025MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 250MCG (10 UNITS)

Frequency: DAILY

Timing: Run Based on Dr Recommendation for Fertilization

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.025MG PER UNIT

Category: GONADOTROPIN RELEASING HORMONE

Description

STIMULATES GONADOTROPIN RELEASE - RELEASES LH AND FSH PROMOTING THE PRODUCTION OF TESTOSTERONE - TREATS HYPOGONADISM

Specifications

Amount in Vial: 10MG

BAC Water: 2ML

Amount per Unit: 0.05MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 250MCG (5 UNITS)

Frequency: DAILY

Timing: Run Based on Dr Recommendation for Fertilization

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.05MG PER UNIT

Category: REPRODUCTIVE HEALTH

Description

TREATS HYPOGONADISM BY STIMULATING THE TESTES TO PRODUCE MORE TESTOSTERONE AND SPERM - IN WOMEN, USED TO INDUCE OVULATION AND FERTILIZATION

Specifications

Amount in Vial: 5000IU

BAC Water: 2ML

Amount per Unit: 25IU PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 500IU TO 1000IU (20 TO 40 UNITS)

Frequency: TWICE PER WEEK

Timing: Run 2 To 3 Times A Year Based On Needs and Based On Fertilization and Gonad Health

Dose Calculator

Target Dose (mg)

Units Needed

Based on 25IU PER UNIT

Category: REPRODUCTIVE HEALTH

Description

EFFECTIVE PEPTIDE FOR HORMONE BALANCE, REPRODUCTIVE HEALTH, AND WELLNESS

Specifications

Amount in Vial: 5MG

BAC Water: 2ML

Amount per Unit: 0.025MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 100MCG TO 200MCG (4 - 8 UNITS)

Frequency: WHEN NEEDED

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.025MG PER UNIT

Category: HEALING AND REPAIR

Description

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide of 15 amino acids, originally isolated from human gastric juice. It is one of the most extensively studied healing peptides in preclinical research, with over 500 published studies from 1993 through 2025. Its primary mechanisms include activation of the VEGFR2 signaling pathway to promote angiogenesis (new blood vessel formation), ERK1/2 signaling to enhance fibroblast activity and endothelial cell migration, upregulation of growth hormone receptor expression, and reduction of inflammatory cytokines. In animal models, BPC-157 has demonstrated protective and regenerative effects across muscle, tendon, ligament, bone, gut lining, heart, and nervous system tissue — earning the descriptors neuroprotective, gastroprotective, cardioprotective, and musculoskeletal protective. It is metabolized in the liver with a half-life under 30 minutes and cleared by the kidneys. As of 2025, three small pilot studies have been conducted in humans; larger controlled trials are pending. For research and educational purposes only. Not FDA-approved. Consult a qualified healthcare professional.

Specifications

Amount in Vial: 5MG

BAC Water: 2ML

Amount per Unit: 0.025MG PER UNIT

Injection Type: SUBCUTANEOUS OR IM

Recommended Dose: 250MCG TO 750MCG (10 TO 30 UNITS)

Frequency: DAILY

Timing: Can Inject Locally Near Injury - Works in Synergy with TB-500

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.025MG PER UNIT

Category: HEALING AND REPAIR

Description

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide of 15 amino acids, originally isolated from human gastric juice. It is one of the most extensively studied healing peptides in preclinical research, with over 500 published studies from 1993 through 2025. Its primary mechanisms include activation of the VEGFR2 signaling pathway to promote angiogenesis (new blood vessel formation), ERK1/2 signaling to enhance fibroblast activity and endothelial cell migration, upregulation of growth hormone receptor expression, and reduction of inflammatory cytokines. In animal models, BPC-157 has demonstrated protective and regenerative effects across muscle, tendon, ligament, bone, gut lining, heart, and nervous system tissue — earning the descriptors neuroprotective, gastroprotective, cardioprotective, and musculoskeletal protective. It is metabolized in the liver with a half-life under 30 minutes and cleared by the kidneys. As of 2025, three small pilot studies have been conducted in humans; larger controlled trials are pending. For research and educational purposes only. Not FDA-approved. Consult a qualified healthcare professional.

Specifications

Amount in Vial: 10MG

BAC Water: 2ML

Amount per Unit: 0.05MG PER UNIT

Injection Type: SUBCUTANEOUS OR IM

Recommended Dose: 250MCG TO 750MCG (5 TO 15 UNITS)

Frequency: DAILY

Timing: Can Inject Locally Near Injury - Works in Synergy with TB-500

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.05MG PER UNIT

Category: HEALING AND REPAIR

Description

TB-500 is a synthetic 7-amino acid peptide corresponding to amino acids 17–23 of thymosin beta-4 (Tβ4), a naturally occurring 43-amino acid protein found at high concentrations in blood platelets and wound fluid. Its central mechanism is G-actin sequestration — by binding to monomeric actin, TB-500 regulates cytoskeletal organization and enables rapid cell migration essential for tissue repair. Different segments of the molecule address distinct functions: amino acids 1–4 drive anti-inflammatory and anti-fibrotic effects; amino acids 1–15 contribute to anti-apoptotic properties; amino acids 17–23 handle actin binding, angiogenesis, and dermal wound repair. In preclinical wound models, TB-500 administration increased re-epithelialization by 42% at day 4 and 61% at day 7 compared to controls, with thicker collagen fiber formation and reduced scarring. Research has also explored its cardioprotective effects following cardiac injury, spinal cord neuroprotection, and corneal wound healing. A 2024 study confirmed activation of the Wnt/β-catenin pathway, a primary driver of cell proliferation and tissue homeostasis. TB-500 is frequently studied alongside BPC-157 due to their complementary mechanisms. For research and educational purposes only. Not FDA-approved.

Specifications

Amount in Vial: 5MG

BAC Water: 1ML

Amount per Unit: 0.05MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 2.5 TO 5MG (50 TO 100 UNITS)

Frequency: TWICE PER WEEK

Timing: Works in Synergy with BPC-157

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.05MG PER UNIT

Category: HEALING AND REPAIR

Description

TB-500 is a synthetic 7-amino acid peptide corresponding to amino acids 17–23 of thymosin beta-4 (Tβ4), a naturally occurring 43-amino acid protein found at high concentrations in blood platelets and wound fluid. Its central mechanism is G-actin sequestration — by binding to monomeric actin, TB-500 regulates cytoskeletal organization and enables rapid cell migration essential for tissue repair. Different segments of the molecule address distinct functions: amino acids 1–4 drive anti-inflammatory and anti-fibrotic effects; amino acids 1–15 contribute to anti-apoptotic properties; amino acids 17–23 handle actin binding, angiogenesis, and dermal wound repair. In preclinical wound models, TB-500 administration increased re-epithelialization by 42% at day 4 and 61% at day 7 compared to controls, with thicker collagen fiber formation and reduced scarring. Research has also explored its cardioprotective effects following cardiac injury, spinal cord neuroprotection, and corneal wound healing. A 2024 study confirmed activation of the Wnt/β-catenin pathway, a primary driver of cell proliferation and tissue homeostasis. TB-500 is frequently studied alongside BPC-157 due to their complementary mechanisms. For research and educational purposes only. Not FDA-approved.

Specifications

Amount in Vial: 10MG

BAC Water: 1ML

Amount per Unit: 0.1MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 2.5 TO 5MG (25 TO 50 UNITS)

Frequency: TWICE PER WEEK

Timing: Works in Synergy with BPC-157

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.1MG PER UNIT

Category: HEALING AND REPAIR

Description

The Wolverine Blend combines BPC-157 and TB-500, two of the most studied healing peptides in preclinical research, targeting complementary tissue repair pathways in a single vial. BPC-157 works primarily through VEGFR2 and ERK1/2 signaling to promote angiogenesis, reduce inflammatory cytokines, and activate growth hormone receptors in tendon and muscle cells. TB-500 works through G-actin sequestration to enhance cell migration, reduce fibrosis, and accelerate re-epithelialization. Together they address vascularization, cellular mobility, inflammation control, and structural tissue rebuilding simultaneously. Researchers frequently combine these peptides because their mechanisms are additive rather than redundant — BPC-157 promotes new blood vessel formation while TB-500 drives the migration of repair cells into damaged tissue. The combination has shown promise in preclinical models for musculoskeletal injuries, gut healing, skin repair, and general tissue regeneration. For research and educational purposes only. Not FDA-approved.

Specifications

Amount in Vial: 20MG

BAC Water: 2ML

Amount per Unit: 0.01MG PER UNIT

Injection Type: SUBCUTANEOUS OR IM

Recommended Dose: 500MCG TO 1MG (10 TO 20 UNITS)

Frequency: 5-7 DAYS PER WEEK

Timing: Do Not Inject Near Injury Site

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.01MG PER UNIT

Category: GUT HEALING

Description

BPC-157 in oral tablet form is specifically studied for gastrointestinal applications. Unlike injectable BPC-157 which distributes systemically, oral administration concentrates the peptide in the GI tract — making it the preferred research route for gut lining repair, inflammatory bowel disease models, NSAID-induced gastric injury, and intestinal fistula healing. BPC-157 is notably chemically stable in gastric juice (it was originally isolated from gastric juice), allowing it to retain biological activity through the digestive tract. A 2025 systematic review published in the American Journal of Gastroenterology synthesized 36 studies (1993–2025) confirming BPC-157's cytoprotective and pro-healing effects across GI ulcer, anastomotic site repair, IBD models, and NSAID-induced injury — with the reviewers noting preclinical safety with no adverse organ system effects. Oral BPC-157 is frequently studied for gastroprotection and leaky gut conditions. Works synergistically with injectable TB-500 for systemic healing goals. For research and educational purposes only.

Specifications

Amount in Vial: 15MG (30 Tablets)

BAC Water: N/A

Amount per Unit: 500MCG PER TABLET

Injection Type: ORAL TABLETS

Recommended Dose: 500MCG TO 1000MCG (1 TO 2 TABLETS)

Frequency: DAILY

Timing: As Needed Take with Meals

Dose Calculator

Target Dose (mg)

Units Needed

Based on 500MCG PER TABLET

Category: LONGEVITY

Description

Epithalon (epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from epithalamin, a natural polypeptide produced by the pineal gland. Its primary researched mechanism is activation of telomerase — the enzyme responsible for maintaining and extending the protective telomere caps at the ends of DNA strands. Telomeres shorten with each cell division; critically shortened telomeres trigger cellular senescence. Epithalon is one of only a small number of compounds that has demonstrated telomerase activation in both in vitro and animal studies, positioning it as a significant subject of longevity research. Secondary mechanisms include restoration of melatonin secretion via pineal gland normalization, antioxidant activity, and modulation of neuroendocrine function. In Russian research spanning over 30 years, Epithalon-treated animals showed increased lifespan, reduced tumor incidence, and improved physiological markers of aging. Human studies remain limited. For research and educational purposes only.

Specifications

Amount in Vial: 10MG

BAC Water: 1ML

Amount per Unit: 0.1MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 10MG (100 UNITS)

Frequency: 20 BOTTLE CYCLE (FULL BOTTLE DAILY FOR 20 DAYS)

Timing: 2x to 3x Annually

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.1MG PER UNIT

Category: LONGEVITY

Description

Epithalon (epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from epithalamin, a natural polypeptide produced by the pineal gland. Its primary researched mechanism is activation of telomerase — the enzyme responsible for maintaining and extending the protective telomere caps at the ends of DNA strands. Telomeres shorten with each cell division; critically shortened telomeres trigger cellular senescence. Epithalon is one of only a small number of compounds that has demonstrated telomerase activation in both in vitro and animal studies, positioning it as a significant subject of longevity research. Secondary mechanisms include restoration of melatonin secretion via pineal gland normalization, antioxidant activity, and modulation of neuroendocrine function. In Russian research spanning over 30 years, Epithalon-treated animals showed increased lifespan, reduced tumor incidence, and improved physiological markers of aging. Human studies remain limited. For research and educational purposes only.

Specifications

Amount in Vial: 50MG

BAC Water: 2ML

Amount per Unit: 0.25MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 10MG TO 20MG (40 TO 80 UNITS)

Frequency: 4 BOTTLE CYCLE OVER 10 TO 20 DAYS

Timing: 3x Annually

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.25MG PER UNIT

Category: BRAIN + MOOD

Description

INNOVATIVE PEPTIDE FOR NEUROPROTECTION, COGNITIVE SUPPORT, AND MOOD ENHANCEMENT

Specifications

Amount in Vial: 10MG

BAC Water: 1ML

Amount per Unit: 0.1MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 300MCG TO 1MG (3 TO 10 UNITS)

Frequency: DAILY

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.1MG PER UNIT

Category: BRAIN + MOOD

Description

NAD+ (nicotinamide adenine dinucleotide) is an essential coenzyme present in every cell of the body. While technically a coenzyme rather than a peptide, injectable NAD+ is included here because it participates in the same mitochondrial optimization protocols as peptides like MOTS-c and SS-31. NAD+ is required for the electron transport chain and oxidative phosphorylation — without sufficient NAD+, mitochondria cannot efficiently convert nutrients into ATP. It also participates in over 500 enzymatic reactions and is the substrate required for sirtuin activation (SIRT1–SIRT7, the longevity-linked enzyme family), PARP-mediated DNA repair, and CD38-driven immune signaling. Human studies confirm NAD+ levels decline approximately 50% between ages 40 and 60. Injectable NAD+ bypasses the conversion steps required for oral precursors like NMN and nicotinamide riboside, delivering direct bioavailability. A 2024 meta-analysis in Nature Metabolism confirmed the safety and efficacy profile of direct NAD+ supplementation approaches. For research and educational purposes only.

Specifications

Specifications

Amount in Vial: 1MG

BAC Water: 1ML

Amount per Unit: 0.01MG PER UNIT

Injection Type: INTRAMUSCULAR

Recommended Dose: 200MCG (20 UNITS)

Frequency: 4 BOTTLE CYCLE OVER 20 DAYS

Timing: 3x Annually

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.01MG PER UNIT

Category: MITOCHONDRIAL FUNCTION

Description

MOTS-c (Mitochondrial ORF of the 12S rRNA type-c) is a 16-amino acid peptide uniquely encoded within the mitochondrial genome — one of the few known peptides not originating from nuclear DNA. This gives it a direct and fundamental relationship with mitochondrial metabolic state. Under metabolic stress, MOTS-c translocates from mitochondria to the cell nucleus, where it binds stress-response transcription factors NRF2 and ATF1 to reprogram cellular metabolism. Its primary signaling mechanism activates AMPK (AMP-activated protein kinase) — the same master metabolic switch triggered by intense exercise — which drives glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. In animal research: a 2021 Nature Communications study showed MOTS-c enhanced physical performance across age groups; a 2022 study showed a single dose improved running time by 12% and distance by 15%; a 2025 Nature study demonstrated MOTS-c prevents pancreatic islet cell senescence, reducing diabetes progression. MOTS-c levels decline approximately 21% between ages 18–30 and ages 70–81. For research and educational purposes only.

Specifications

Amount in Vial: 10MG

BAC Water: 1ML

Amount per Unit: 0.1MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 5MG - 10MG (50 UNITS - 100 UNITS)

Frequency: 1 INJECTION EVERY 5 DAYS FOR 20 DAYS

Timing: 3x Annually - If Type 2 Diabetic 1mg EOD

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.1MG PER UNIT

Category: MITOCHONDRIAL FUNCTION

Description

SS-31 (also known as elamipretide, Bendavia, and Forzinity) is a synthetic aromatic-cationic tetrapeptide engineered to concentrate at the inner mitochondrial membrane at levels approximately 1,000–5,000 times higher than surrounding cellular tissue. Its mechanism is precise: SS-31 binds cardiolipin, a phospholipid found exclusively in the inner mitochondrial membrane that holds the electron transport chain machinery in place. As cardiolipin degrades with age and oxidative stress, the electron transport chain loosens, energy output drops, and reactive oxygen species (ROS) production spikes. SS-31 stabilizes cardiolipin, tightening respiratory complexes I, III, and IV, reducing ROS production, and restoring efficient ATP generation. In aged mice, a single SS-31 injection restored in vivo mitochondrial energetics to young-mouse levels within one hour. SS-31 (as elamipretide/Forzinity) received FDA accelerated approval in September 2025 for Barth syndrome, a rare genetic disorder defined by defective cardiolipin remodeling — making it the first mitochondria-targeted therapeutic approved in the United States. For research purposes in non-Barth applications, SS-31 remains investigational. For research and educational purposes only.

Specifications

Amount in Vial: 14MG

BAC Water: 1.2ML

Amount per Unit: 0.116MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 4.67MG (40 UNITS)

Frequency: 7 BOTTLE CYCLE 1X PER DAY FOR 21 DAYS 2 TO 3X PER YEAR

Timing: Best To Use Before Running A MOTS-C Cycle

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.116MG PER UNIT

Category: BRAIN + WEIGHTLOSS

Description

SNDRI - ENHANCE MOOD - SUPPRESS APPETITE - INCREASED ENERGY - COGNITIVE FUNCTION

Specifications

Amount in Vial: 15MG (30 Tablets)

BAC Water: N/A

Amount per Unit: 500MCG PER TABLET

Injection Type: ORAL TABLETS

Recommended Dose: 250MCG TO 1000MCG (1/2 TO 2 TABLETS)

Frequency: DAILY

Timing: Fasted Upon Waking

Dose Calculator

Target Dose (mg)

Units Needed

Based on 500MCG PER TABLET

Category: BRAIN + WEIGHTLOSS

Description

SNDRI - ENHANCE MOOD - SUPPRESS APPETITE - INCREASED ENERGY - COGNITIVE FUNCTION

Specifications

Amount in Vial: 50MG (100 Tablets)

BAC Water: N/A

Amount per Unit: 500MCG PER TABLET

Injection Type: ORAL TABLETS

Recommended Dose: 250MCG TO 1000MCG (1/2 TO 2 TABLETS)

Frequency: DAILY

Timing: Fasted Upon Waking

Dose Calculator

Target Dose (mg)

Units Needed

Based on 500MCG PER TABLET

Category: DELTA SLEEP/DETOX/WITHDRAWAL

Description

RESETS CIRCADIAN CLOCK - SUPPORTS NERVOUS AND HORMONAL SYSTEM - SUPPORT FOR ALCOHOL AND OPIOID WITHDRAWAL

Specifications

Amount in Vial: 5MG

BAC Water: 1ML

Amount per Unit: 0.05MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 500MCG TO 1MG (10 TO 20 UNITS)

Frequency: AS NEEDED BEFORE BED

Timing: Delta Sleep Inducing Peptide

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.05MG PER UNIT

Category: LIBIDO/ED

Description

SIGNALS CENTRAL NERVOUS SYSTEM TO ENHANCE BLOOD FLOW, AROUSAL AND LIBIDO IN MEN AND WOMEN

Specifications

Amount in Vial: 5MG

BAC Water: 1ML

Amount per Unit: 0.05MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 500MCG (10 UNITS)

Frequency: AS NEEDED (2 HOURS BEFORE SEXUAL ACTIVITY)

Timing: Not To Exceed 20 Units (Consult With Doctor)

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.05MG PER UNIT

Category: LIBIDO/ED

Description

SIGNALS CENTRAL NERVOUS SYSTEM TO ENHANCE BLOOD FLOW, AROUSAL AND LIBIDO IN MEN AND WOMEN

Specifications

Amount in Vial: 10MG

BAC Water: 2ML

Amount per Unit: 0.05MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 500MCG TO 1MG (10 TO 20 UNITS)

Frequency: AS NEEDED (2 HOURS BEFORE SEXUAL ACTIVITY)

Timing: Not To Exceed 20 Units (Consult With Doctor)

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.05MG PER UNIT

Category: MELANIN/LIBIDO

Description

USED FOR TANNING (MELANOGENESIS) - APPETITE SUPPRESSION AND ENHANCED SEXUAL STIMULUS

Specifications

Amount in Vial: 10MG

BAC Water: 1ML

Amount per Unit: 0.1MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 500MCG TO 1MG (5 TO 10 UNITS)

Frequency: EVERY OTHER DAY

Timing: Use 30 Minutes Before Tanning

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.1MG PER UNIT

Category: MELANIN/LIBIDO

Description

USED FOR TANNING (MELANOGENESIS) - APPETITE SUPPRESSION AND ENHANCED SEXUAL STIMULUS

Specifications

Amount in Vial: 10MG

BAC Water: 1ML

Amount per Unit: 0.1MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 500MCG TO 1MG (5 TO 10 UNITS)

Frequency: BEFORE TANNING

Timing: Use 30 Minutes Before Tanning

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.1MG PER UNIT

Category: BRAIN + REPAIR

Description

BRAIN FUNCTION - STIMULATES NEUROGENESIS - ENHANCES COGNITION - MOOD REGULATION - MEMORY AND LEARNING

Specifications

Amount in Vial: 10MG

BAC Water: 1ML

Amount per Unit: 0.1MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 500MCG TO 2MG (5 TO 20 UNITS)

Frequency: DAILY

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.1MG PER UNIT

Category: IMMUNITY

Description

ANTIMICROBIAL, ANTIVIRAL AND ANTIBIOFILM - USED AS NATURAL ANTIBIOTIC - FIGHTS LUNG AND GUT INFECTION

Specifications

Amount in Vial: 5MG

BAC Water: 2ML

Amount per Unit: 0.025MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 250MCG (10 UNITS)

Frequency: WHILE SICK OR TO PREVENT ILLNESS

Timing: Stop Use When Feeling Healthy

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.025MG PER UNIT

Category: IMMUNITY

Description

ANTIMICROBIAL, ANTIVIRAL AND ANTIBIOFILM - USED AS NATURAL ANTIBIOTIC - FIGHTS LUNG AND GUT INFECTION

Specifications

Amount in Vial: 5MG

BAC Water: 2ML

Amount per Unit: 0.025MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 300MCG TO 1MG (12 TO 50 UNITS)

Frequency: DURING ILLNESS

Timing: Stop Use When Feeling Healthy

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.025MG PER UNIT

Category: HAIR/SKIN/COLLAGEN

Description

GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine at concentrations that decline significantly with age — from approximately 200 ng/mL at age 20 to 80 ng/mL by age 60. Its mechanisms are multi-directional: GHK-Cu activates approximately 31% of human genes associated with tissue remodeling and repair, upregulates collagen and elastin synthesis, promotes antioxidant enzyme activity, modulates TGF-β to reduce fibrosis, and inhibits inflammatory cytokines. In skin research, it has demonstrated acceleration of wound healing, reduction of fine lines and wrinkles through collagen restoration, and improvement in skin laxity and firmness. In hair research, it promotes hair follicle size and has shown potential for androgenic alopecia. It also stimulates nerve outgrowth and has shown bone repair potential through increased osteoblast activity. For research and educational purposes only.

Specifications

Amount in Vial: 50MG

BAC Water: 2ML

Amount per Unit: 0.25MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 1MG TO 2MG (4 TO 8 UNITS)

Frequency: DAILY

Timing: 30 Days On / 14 Days Off

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.25MG PER UNIT

Category: HAIR/SKIN/COLLAGEN

Description

GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine at concentrations that decline significantly with age — from approximately 200 ng/mL at age 20 to 80 ng/mL by age 60. Its mechanisms are multi-directional: GHK-Cu activates approximately 31% of human genes associated with tissue remodeling and repair, upregulates collagen and elastin synthesis, promotes antioxidant enzyme activity, modulates TGF-β to reduce fibrosis, and inhibits inflammatory cytokines. In skin research, it has demonstrated acceleration of wound healing, reduction of fine lines and wrinkles through collagen restoration, and improvement in skin laxity and firmness. In hair research, it promotes hair follicle size and has shown potential for androgenic alopecia. It also stimulates nerve outgrowth and has shown bone repair potential through increased osteoblast activity. For research and educational purposes only.

Specifications

Amount in Vial: 75MG

BAC Water: 2ML

Amount per Unit: 0.375MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 1MG TO 2MG (3 TO 5 UNITS)

Frequency: DAILY

Timing: 30 Days On / 14 Days Off

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.375MG PER UNIT

Category: ANTI-VIRAL, ANTI-MICROBIAL

Description

REDUCES INFLAMMATORY CYTOKINES - PROMOTES WOUND HEALING - ANTIMICROBIAL - HELPS WITH INFLAMMATORY BOWEL DISEASE

Specifications

Amount in Vial: 5MG

BAC Water: 1ML

Amount per Unit: 0.05MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 200MCG TO 500MCG (5 TO 10 UNITS)

Frequency: BASED ON INJURY

Timing: After Surgery, Preventative or Illness

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.05MG PER UNIT

Category: ANTI INFLAMMATORY

Description

MODULATES INFLAMMATORY PATHWAYS - PROMOTES TISSUE REPAIR - ANTIOXIDANT - SUPPORTS GUT HEALTH

Specifications

Amount in Vial: 600MG

BAC Water: 2ML

Amount per Unit: 3MG PER UNIT

Injection Type: INTRAMUSCULAR

Recommended Dose: 45-90 MG (15 TO 30 UNITS)

Frequency: DAILY

Dose Calculator

Target Dose (mg)

Units Needed

Based on 3MG PER UNIT

Category: ANTI-VIRAL + ANTI CANCER + IMMUNITY

Description

THYMOSIN ALPHA-1 STIMULATES IMMUNE SYSTEM - PRODUCING AND ACTIVATING T-CELLS, DENDRITIC CELLS, AND NATURAL KILLER CELLS - ERADICATES BACTERIA, FUNGI AND VIRUSES

Specifications

Amount in Vial: 16.4MG

BAC Water: 1ML

Amount per Unit: 0.164MG PER UNIT

Injection Type: INTRAMUSCULAR

Recommended Dose: 3MG TO 8MG (20 - 50 UNITS)

Frequency: WHEN SICK 2X PER WEEK

Timing: Use When Sick 4x Per Year

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.164MG PER UNIT

Category: ANTI-VIRAL + ANTI CANCER + IMMUNITY

Description

THYMOSIN ALPHA-1 STIMULATES IMMUNE SYSTEM - PRODUCING AND ACTIVATING T-CELLS, DENDRITIC CELLS, AND NATURAL KILLER CELLS - ERADICATES BACTERIA, FUNGI AND VIRUSES

Specifications

Amount in Vial: 10MG

BAC Water: 1ML

Amount per Unit: 0.1MG PER UNIT

Injection Type: INTRAMUSCULAR

Recommended Dose: 3MG TO 8MG (30 - 80 UNITS)

Frequency: WHEN SICK 2X PER WEEK

Timing: Use When Sick 4x Per Year

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.1MG PER UNIT

Category: SKIN + TISSUE HEALING

Description

ENHANCE SKIN HEALTH - ACCELERATE HEALING - SUPPORT OVERALL TISSUE REGENERATION

Specifications

Amount in Vial: 42MG

BAC Water: 3ML

Amount per Unit: 0.14MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 900MCG TO 1800MCG (10 - 20 UNITS)

Frequency: DAILY

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.14MG PER UNIT

Category: MUSCLE DEVELOPMENT

Description

MGF (Mechano Growth Factor) is an alternative splice variant of the IGF-1 gene, produced locally in skeletal muscle in response to mechanical stress and microtrauma such as resistance training. Unlike systemic IGF-1 which circulates throughout the body, MGF acts as a local first-responder — its mRNA expression peaks within 2-3 hours after heavy resistance exercise and is blunted significantly with aging, which is why muscle recovery slows as we get older. Its primary mechanism is satellite cell activation: MGF signals quiescent muscle stem cells to proliferate and begin the repair cascade, supplying more building blocks for subsequent tissue rebuilding. Secondary mechanisms include activation of the MAPK-ERK1/2 pathway promoting osteoblast proliferation, cardioprotection via anti-apoptotic signaling, and chondrocyte protection against mechanical overload-induced cell death. Native MGF has a half-life of only 5-7 minutes, limiting practical application. Note: MGF is referenced in the 3X and 4X blend formulations on this site. This standalone entry covers the unmodified research peptide. For extended half-life, see PEG-MGF. For research and educational purposes only.

Specifications

Amount in Vial: 2MG

BAC Water: 2ML

Amount per Unit: 0.01MG PER UNIT

Injection Type: INTRAMUSCULAR

Recommended Dose: 100MCG TO 200MCG (10 TO 20 UNITS)

Frequency: DAILY (INJECT POST-WORKOUT INTO TARGET MUSCLE)

Timing: Immediately post-training into the worked muscle group. Works synergistically with IGF1-LR3.

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.01MG PER UNIT

Category: MUSCLE DEVELOPMENT

Description

PEG-MGF (Pegylated Mechano Growth Factor) is a chemically modified version of MGF in which polyethylene glycol molecules are attached to the peptide structure through PEGylation. This single modification solves MGF's primary limitation — extending the half-life from 5-7 minutes to several hours or days, allowing twice-weekly rather than daily dosing and enabling the peptide to remain in circulation long enough to exert meaningful systemic effects. PEG-MGF works by activating muscle satellite cells — the stem-like progenitor cells responsible for muscle repair and hypertrophy — stimulating their proliferation and delaying premature differentiation, thereby expanding the pool of repair cells available after training-induced microtrauma. Research has also demonstrated anti-apoptotic effects in cardiac myocytes, bone defect healing via osteoblast proliferation (1.4x greater effect than IGF-1 in one study), and cartilage protection. Because PEGylation distributes the peptide systemically rather than locally, PEG-MGF can be injected subcutaneously rather than requiring intramuscular injection into specific muscle groups. Commonly studied alongside IGF1-LR3 in a complementary protocol: PEG-MGF post-workout for repair signaling, IGF1-LR3 on rest days for growth. For research and educational purposes only.

Specifications

Amount in Vial: 2MG

BAC Water: 2ML

Amount per Unit: 0.01MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 200MCG TO 400MCG (20 TO 40 UNITS)

Frequency: 2 TO 3 TIMES PER WEEK

Timing: Post-workout administration. 5-6 week cycles. Stack with IGF1-LR3 on alternating days.

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.01MG PER UNIT

Category: BRAIN + MOOD

Description

Noopept (chemical name N-phenylacetyl-L-prolylglycine ethyl ester, also known as Omberacetam or GVS-111) is a synthetic dipeptide developed in Russia in 1996 as an orally bioavailable analogue of Piracetam — approximately 1,000 times more potent per dose. It is one of the rare research peptides that works effectively via oral administration, crossing the blood-brain barrier within minutes. Noopept is a prodrug metabolized in the body into its active form cycloprolylglycine, an endogenous dipeptide that acts as a positive modulator of AMPA receptors and activates the BDNF/TrkB signaling pathway. Additional mechanisms include activation of the Hypoxia-Inducible Factor 1 (HIF-1) transcription pathway and upregulation of both BDNF and NGF expression. In Russian clinical trials across 30+ years with over 1,000 subjects, Noopept demonstrated 20-30% improvements on MMSE cognitive scores versus placebo in patients with mild cognitive impairment. It also showed anxiolytic effects. Standard protocol: 10mg twice daily for 1.5-3 month courses with at least 1 month break. Oral administration — no reconstitution required. For research and educational purposes only.

Specifications

Amount in Vial: 30MG (30 TABLETS x 1MG)

BAC Water: N/A — ORAL TABLETS

Amount per Unit: 10MG PER TABLET

Injection Type: ORAL TABLETS

Recommended Dose: 10MG TO 30MG (1 TO 3 TABLETS)

Frequency: DAILY (TAKE WITH OR AFTER MEALS)

Timing: Morning or split morning/midday. Last dose no later than mid-afternoon. Pair with Alpha-GPC 300mg or citicoline 250mg to prevent headaches. 1.5-3 month cycles with 1+ month break between.

Dose Calculator

Target Dose (mg)

Units Needed

Based on 10MG PER TABLET

Category: BRAIN + REPAIR

Description

Pinealon (also known as the EDR peptide, from its three amino acids Glutamic acid, Aspartic acid, Arginine) is a synthetic tripeptide developed by Professor Vladimir Khavinsky at the St. Petersburg Institute of Bioregulation and Gerontology, classified as a geroprotector — a compound designed to slow age-related biological decline. It is one of the smallest known neuroprotective peptides, with a molecular weight of 418.4 g/mol that allows it to cross the blood-brain barrier via the PEPT2 transporter system. Pinealon's primary mechanism is epigenetic gene regulation: it directly influences the expression of genes involved in neurogenesis, memory formation, and circadian rhythm by entering cell nuclei and modulating transcription factor activity. It also increases irisin levels — a peptide linked to neuron proliferation and differentiation — and demonstrates antioxidant activity protecting neurons from oxidative and excitotoxic damage. Research highlights include: 59.4% of patients recovering from traumatic brain injury showed measurable memory improvement when Pinealon was added to standard rehabilitation; it is one of the active compounds in Cortexin, a multi-peptide drug used clinically in several countries for TBI treatment. Commonly stacked with Epithalon for the complete Khavinsky bioregulator protocol, and with PE-22-28 and Selank for the Calm and Clarity blend. For research and educational purposes only.

Specifications

Amount in Vial: 20MG (20 TABLETS x 1MG)

BAC Water: N/A — ORAL TABLETS

Amount per Unit: 1MG PER TABLET

Injection Type: ORAL TABLETS

Recommended Dose: 10MG TO 20MG (10 TO 20 TABLETS)

Frequency: DAILY

Timing: Take daily in a 20-30 day cycle, 2-3 times annually. Stack with Epithalon for Khavinsky longevity protocol. Stack with PE-22-28 and Selank for the Calm and Clarity nootropic protocol.

Dose Calculator

Target Dose (mg)

Units Needed

Based on 1MG PER TABLET

Category: MITOCHONDRIAL FUNCTION

Description

Humanin is a 21-amino acid mitochondrial-derived peptide first discovered in 2001 from the brain tissue of an Alzheimer's disease patient — researchers noticed that specific brain cells were surviving in an otherwise degenerating environment and traced the protective signal to Humanin, encoded within the 16S rRNA region of the mitochondrial genome. Along with MOTS-c and SS-31, Humanin forms the core trio of mitochondrial-targeted research peptides. Its primary mechanism is cytoprotection: Humanin works by blocking pro-apoptotic proteins — particularly Bax — at the mitochondrial membrane, preventing the release of cytochrome c that triggers programmed cell death. It also reduces beta-amyloid toxicity in neurons. In animal research, Humanin has demonstrated protection of neurons against Alzheimer's-associated apoptosis, prion disease, and forms of dementia; reduction of oxidative stress in retinal pigment epithelium; cytoprotective effects in heart, muscle, and blood vessel cells; and improved insulin sensitivity in aging models. Humanin levels decline measurably with age and are lower in individuals with metabolic disease. Unlike MOTS-c (which drives metabolic adaptation) and SS-31 (which repairs the inner membrane), Humanin functions primarily as a cellular shield protecting existing cells from stress-induced death. The three peptides are mechanistically complementary and increasingly studied together in longevity protocols. For research and educational purposes only.

Specifications

Amount in Vial: 5MG

BAC Water: 1ML

Amount per Unit: 0.05MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 500MCG TO 2MG (10 TO 40 UNITS)

Frequency: EVERY OTHER DAY OR 3X PER WEEK

Timing: Morning SubQ injection. Benefits are long-term and cellular — expect 4-8 weeks before noticeable effects. Completes the mitochondrial trio alongside MOTS-c and SS-31.

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.05MG PER UNIT

Category: ANTI INFLAMMATORY

Description

VIP (Vasoactive Intestinal Peptide) is a 28-amino acid neuropeptide and potent endogenous immune modulator found in the brain, gut, and throughout the nervous system. VIP binds to VPAC1 and VPAC2 receptors on immune cells, reducing production of pro-inflammatory cytokines including IL-6 and TNF-alpha by up to 40% in controlled research settings, without broadly suppressing the immune system — a critical distinction from corticosteroids. This selectivity makes it relevant in research for mast cell activation syndrome (MCAS), chronic inflammatory response syndrome (CIRS/mold illness), inflammatory bowel disease, pulmonary hypertension, COPD, and rheumatoid arthritis. VIP also synchronizes the suprachiasmatic nucleus (the brain's master clock) with light-dark cycles, making it relevant in circadian rhythm and sleep disorder research. Administration note: VIP has a plasma half-life of only 2-3 minutes when administered systemically. Intranasal delivery routes bypass this issue by achieving direct CNS transport via olfactory nerve at concentrations 10-15x higher than subcutaneous dosing. Titration should be gradual — start low and increase over 2-3 weeks. Vasodilatory flushing is common during initial administration and typically resolves as the body adapts. For research and educational purposes only. Consult a qualified healthcare professional.

Specifications

Amount in Vial: 10MG

BAC Water: 2ML

Amount per Unit: 0.05MG PER UNIT

Injection Type: SUBCUTANEOUS OR INTRANASAL

Recommended Dose: 50MCG TO 200MCG (1 TO 4 UNITS)

Frequency: DAILY OR TWICE DAILY

Timing: Titrate up gradually from 50mcg. Intranasal preferred for CNS and circadian applications. SubQ for systemic anti-inflammatory use. Commonly used in MCAS stacks alongside LL-37, KPV, and TA-1.

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.05MG PER UNIT

Category: IMMUNITY

Description

Thymalin is a natural peptide bioregulator extracted from the thymus gland, developed by Professor Khavinsky's team at the St. Petersburg Institute of Bioregulation and Gerontology. The thymus gland is the primary organ responsible for T-cell development and immune education, but it undergoes progressive atrophy (involution) from early adulthood, shrinking significantly by age 40-50 and contributing to measurable immune decline associated with aging. Thymalin's mechanism operates by restoring thymus function: it normalizes T-lymphocyte activity, regulates the balance between T-helper and T-suppressor cells, and stimulates both cellular and humoral immunity. In Khavinsky's longitudinal research spanning 6-year follow-up periods, elderly patients treated with Thymalin showed significantly reduced mortality rates and improved immune markers compared to control groups. It is classified as a geroprotector — a compound that slows the biological aging of immune function specifically. Thymalin is commonly used in advanced longevity protocols alongside Epithalon (for systemic anti-aging) and TA-1 (which more acutely activates T-cells for infectious challenges). Where TA-1 is used acutely when sick, Thymalin is used cyclically for long-term immune system restoration. For research and educational purposes only.

Specifications

Amount in Vial: 10MG

BAC Water: 2ML

Amount per Unit: 0.05MG PER UNIT

Injection Type: SUBCUTANEOUS OR INTRAMUSCULAR

Recommended Dose: 5MG TO 10MG (50 TO 100 UNITS)

Frequency: DAILY FOR 10 DAYS, 2-3X PER YEAR

Timing: 10-day cycles administered 2-3 times annually. Often paired with Epithalon cycles for the complete Khavinsky longevity protocol. Complements TA-1 for long-term immune restoration.

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.05MG PER UNIT

Category: BRAIN + REPAIR

Description

Dihexa (also known as PNB-0408) is a synthetic angiotensin IV-derived heptapeptide studied primarily for its synaptogenic properties — its ability to stimulate the formation of new synaptic connections in the brain. Its researched mechanism involves activation of the hepatocyte growth factor (HGF) / c-Met signaling pathway, which promotes new dendritic spine formation and synaptic plasticity. Important evidence caveat: the foundational 2014 mechanism paper establishing the HGF/c-Met pathway (Benoist et al., Journal of Pharmacology and Experimental Therapeutics) was formally retracted by Washington State University in April 2025 following findings of falsified and fabricated data. This significantly impacts the mechanistic evidence base. The compound remains heavily searched and widely discussed in the research community, and other preclinical work on synaptic enhancement continues, but users and researchers should approach Dihexa with full awareness of this evidence gap. No approved human clinical trials exist. For research and educational purposes only. Note: foundational mechanism paper retracted April 2025 — evidence base is currently limited. Consult a qualified healthcare professional.

Specifications

Amount in Vial: 10MG

BAC Water: 1ML

Amount per Unit: 0.1MG PER UNIT

Injection Type: SUBCUTANEOUS OR ORAL

Recommended Dose: 10MG TO 40MG

Frequency: DAILY OR EVERY OTHER DAY

Timing: Often dosed orally in community protocols. Cycle length 4-8 weeks. Stack with Semax or BDNF for complementary neuroprotective mechanisms.

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.1MG PER UNIT

Category: BRAIN + MOOD

Description

The Calm and Clarity Blend combines three complementary nootropic peptides — PE-22-28, Pinealon, and Selank — each targeting a distinct cognitive pathway with no mechanism overlap. PE-22-28 works on neuroprotection and BDNF-linked mood stabilization. Pinealon (EDR peptide) targets epigenetic gene regulation of neurogenesis and memory consolidation, crossing the blood-brain barrier to influence transcription directly. Selank modulates GABAergic signaling and serotonin-dopamine balance for acute anxiety reduction and calm focus. Together they address structural cognitive support (Pinealon), acute anxiolytic and focus enhancement (Selank), and mood-stabilizing neuroprotection (PE-22-28) — three mechanisms that work without redundancy. This is one of the most widely referenced pre-mixed nootropic stacks in the peptide research community. All three components are available individually on this site.

Specifications

Amount in Vial: 20MG TOTAL

BAC Water: 2ML

Amount per Unit: 0.1MG PER UNIT

Injection Type: SUBCUTANEOUS

Recommended Dose: 300MCG TO 1MG (3 TO 10 UNITS)

Frequency: DAILY

Timing: Morning or early afternoon. Cycle 20-30 days on with 2-week break.

Dose Calculator

Target Dose (mg)

Units Needed

Based on 0.1MG PER UNIT

Category: MITOCHONDRIAL FUNCTION

Description

The Mito Stack combines the three most researched mitochondrial-targeted compounds available, each addressing a different failure point in the mitochondrial energy system. SS-31 (elamipretide) repairs the inner mitochondrial membrane by binding and stabilizing cardiolipin — the phospholipid that holds the electron transport chain in place. When cardiolipin degrades with age, electron flow becomes inefficient and reactive oxygen species production spikes. SS-31 fixes this structural problem first. MOTS-c then acts as the metabolic reprogramming signal — a mitochondria-encoded peptide that activates AMPK, driving mitochondrial biogenesis, glucose uptake, and fat oxidation. Finally, NAD+ supplies the essential coenzyme substrate that every mitochondrial energy process depends on, restoring the declining NAD+ pool that drops approximately 50% between ages 40 and 60. The protocol sequence matters: SS-31 first to repair membrane integrity, MOTS-c added to build new mitochondrial capacity on a repaired foundation, NAD+ supporting both throughout. SS-31 received FDA accelerated approval as elamipretide/Forzinity for Barth syndrome in September 2025 — the first mitochondria-targeted therapeutic approved in the US. For research and educational purposes only.

Specifications

Amount in Vial: SOLD AS 3-PART CYCLE PROTOCOL

BAC Water: SEE INDIVIDUAL PEPTIDE ENTRIES

Amount per Unit: SEE INDIVIDUAL ENTRIES

Injection Type: SUBCUTANEOUS (SS-31, MOTS-c) / INTRAMUSCULAR (NAD+)

Recommended Dose: SEE INDIVIDUAL PEPTIDE ENTRIES FOR PRECISE DOSING

Frequency: 12-WEEK PROTOCOL — SS-31 WEEKS 1-3, MOTS-C WEEKS 4-8, NAD+ THROUGHOUT

Timing: Phase 1: SS-31 daily for 21 days to restore membrane integrity. Phase 2: Add MOTS-c every 5 days for 20 days. NAD+: 50-150mg IM, 10 units daily or 2x/week throughout. 2-3 cycles per year.

Dose Calculator

Target Dose (mg)

Units Needed

Based on SEE INDIVIDUAL ENTRIES

Advanced Filters

2X Blend: Tesamorelin (10mg) / Ipamorelin (5mg)

2X Blend: CJC No DAC (5mg) / Ipamorelin (5mg)

2X Blend: Tesamorelin (5mg) / Ipamorelin (5mg)

3X Blend: Tesamoralin (5mg) / Ipamorelin (2.5mg) / MGF (500mcg)

4X Blend: Tesamoralin (5mg) / Ipamorelin (2.5mg) / GHRP-2 (5mg) / MGF (500mcg)

GLP-1: 2mg

GLP-1: 5mg

GLP-1: 10mg

GLP-1: 20mg

GLP-1 Dual Agonist: 10mg

GLP-1 Dual Agonist: 30mg

GLP-1 Dual Agonist: 50mg

GLP-1 Dual Agonist: 60mg

GLP-3: 12mg

GLP-3: 24mg

Survodutide: 6mg

AOD-9604: 5mg

Cagrilintide: 10mg

CJC1295 - No DAC: 10mg

CJC1295 - With DAC: 10mg

Tesamorelin: 5mg

Tesamorelin: 10mg

Sermorelin: 10mg

Sermorelin: 5mg

GHRP-2: 5mg

GHRP-6: 5mg

Ipamorelin: 10mg

Hexarelin: 5mg

HGH 10iu: 10IU

IGF1-LR3: 1mg